Explore News By Topic

07/20/2020

Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program

When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute. The study, an international collaboration with The Netherlands Cancer Institute, was published in Nature... Read More

05/30/2020

ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment

A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease. The non-invasive test is less painful and cheaper than tissue biopsies and can help pick out men who... Read More

05/20/2020

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval by the US Food and Drug Administration... Read More

05/15/2020

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy

Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in months... Read More

05/15/2020

VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug

WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male Veterans with COVID-19. In a double-blind randomized controlled trial, VA scientists will compare the drug degarelix (trade name Firmagon) to a placebo... Read More

03/22/2020

Molecular Imaging Could Transform Management of People with Aggressive Cancer

VICTORIA, Australia, March 22, 2020: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for their patients, by determining the extent of disease spread at the time of diagnosis, a randomised... Read More

12/16/2019

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More

12/16/2019

Winship study sheds light on immune control of cancer

Issued by: Emory University Woodruff Health Sciences Center New findings could provide doctors with vital clues about how the immune system prevents cancer from recurring. The study from Winship Cancer Institute of Emory University looked at whether immune cells were present in tumor samples removed from patients with kidney and... Read More

08/22/2019

The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners

The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research institutions. They will receive a total of $2.5 million to support cross-disciplinary pioneering research toward the goal of finding a... Read More

07/23/2019

Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine

Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports. An emerging class of drugs are made up of a radioactive particle that... Read More